Colorectal Cancer
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Global colorectal cancer market intelligence for pharma BD, investors & analysts. Stay ahead with drug development, regulatory updates & clinical trial insights.
Showing 1–8 of 8 articles
Quick answer
NovaPharmaNews Colorectal Cancer hub for FDA covers 8 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
Legend Biotech surges on early in vivo CAR-T data for lymphoma
ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come
Citius Pharmaceuticals Stock Update: Cancer and Anti-Infective Pipeline Insights
ACRP 2026: Immunology Updates & Parexel Hiring Event
Phanes Therapeutics to Present Updated Spevatamig Phase 2 Results for Metastatic Pancreatic Cancer at ASCO 2026
Pfizer Presents LORBRENA and BRAFTOVI Cancer Trial Updates at ASCO 2026
Inhibrx Biosciences to Present Ozekibart (INBRX-109) Clinical Data for Late-Line Colorectal Cancer Treatment
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.